Amicus Therapeutics, Inc. (FOLD) Q1 2019 Earnings Results

Amicus Therapeutics Misses on EPS — Stock Down 4.1%

Amicus Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.1% decline in stock price. The lack of revenue figures and forward guidance may raise concerns among investors about the company's financial health and future performance. The focus on clinical trials suggests that the company is prioritizing long-term growth over short-term financial results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.56	N/A	-72.06%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the current financial performance. They emphasized their commitment to advancing their pipeline despite the losses.

Management did not provide specific guidance for future performance.

The company is focusing on its ongoing clinical trials and product development.

Amicus Therapeutics Misses on EPS — Stock Down 4.1%

Key numbers

Management commentary

Amicus Therapeutics, Inc.

More earnings this week

Amicus Therapeutics Misses on EPS — Stock Down 4.1%

Key numbers

Management commentary